Clinical Trial Update: Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC [Phase 2]

View source ↗

Summary

ClinicalTrials.gov update describes a Phase 2 neoadjuvant trial (NEOSHIFT-RCC) evaluating HIF-inhibitor immunotherapy for renal cell carcinoma; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Status: RECRUITING